CFTR Correctors/Modulators Market Size to Surpass US$ 22.70 Billion by 2031 – Growth Plus Reports


Newark, New Castle, USA, June 06, 2023 (GLOBE NEWSWIRE) — The market analysis of the global CFTR correctors/modulators market was conducted by Growth Plus Reports in 2022 and is valued at US$ 8.93 billion. The market is expected to hit a revenue CAGR of 10.1% to reach US$ 22.70 billion by 2031.

Analysis of the global market for CFTR correctors/modulators indicates that the market revenue share is likely to expand during the forecast period. The chloride ions are transported into and out of cells by the protein known as the cystic fibrosis transmembrane conductance regulator (CFTR).

Get a Free Sample Research Report:


                            CFTR Correctors/Modulators Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 8.93 billion
Revenue Forecast in 2031 US$ 22.70 billion
CAGR 10.1%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Drugs, Distribution Channel, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Key Takeaways: 

  • The United States reports one of the highest rates of cystic fibrosis incidence, with about 40,000 children and adults afflicted, according to 2021 projections from the Journal of Cystic Fibrosis.
  • The rising prevalence of cystic fibrosis is driving the market revenue share.
  • Ivacaftor is a drug that targets the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Recent Development in the CFTR Correctors/Modulators Market: 

  • In September 2022, for children with cystic fibrosis aged 12 to 24 months, Vertex Pharmaceutical’s ORKAMBI, a combination of lumacaftor and ivacaftor, got FDA clearance.

Competitive Landscape

A list of the prominent players operating in the global market for CFTR correctors/modulators includes: 

  • ReCode Therapeutics                          
  • Arcturus Therapeutics 
  • Translate Bio 
  • Abbvie, Inc. 
  • Eloxx Pharmaceuticals Inc.

Request for Customization –

Market Drivers and Restraints: 

The global CFTR correctors/modulators market revenue is driven by the development of new drugs and the increasing availability of genetic testing that can identify patients who may benefit from these treatments. The market is also likely to be shaped by regulatory changes, such as the FDA’s recent approval of Trikafta (elexacaftor/tezacaftor/ivacaftor) for a broader range of CF mutations.

However, these drugs are comparatively expensive and are not accessible to all patients. There is still a need for additional research and development to identify new treatments for Cystic Fibrosis. These factors can restrain the market revenue growth. 

Market Segmentation: 

  • Based on drugs, the global CFTR correctors/modulators market is segmented into Elexacaftor, Tezacaftor, Ivacaftor, and Lumacaftor. 
  • Based on distribution channel, the global CFTR correctors/modulators market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies

Segmentation By Drugs

Based on the drugs, the ivacaftor segment dominates the global CFTR correctors/modulators market with the largest revenue share. This large revenue share is attributed to improved effectiveness in addressing the underlying genetic flaw that causes cystic fibrosis and has also shown improved lung function with reduced exacerbations in patients. 

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global CFTR correctors/modulators market. This large revenue share is because of the high population of patients suffering from cystic fibrosis, increasing healthcare standards, and the presence of key market players in this region. 

Report Coverage 

Growth Plus Reports carried out extensive market research on the CFTR correctors/modulators market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Elexacaftor
    2. Tezacaftor
    3. Ivacaftor
    4. Lumacaftor
    1. Hospital Pharmacies  
    2. Retail Pharmacies      
    3. Online Pharmacies     


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Automated Colony Picking Systems Market by Product Type (Multi Colony Picking System, Single Pin System), Operation (Plate Replication, Colony Picking), End User (Hospital Laboratories, Diagnostic Laboratories) – Global Outlook & Forecast 2023-2031

Lavage Kits Market by Type (Rectal Lavage Kits, Gastric Lavage Kits), End User (Hospitals, Clinics) – Global Outlook and Forecast 2023-2031

Liposome Drug Delivery Market by Product (Liposomal Doxorubicin, Liposomal Amphotericin B, and Liposomal Paclitaxel), Technology (Non-PEGylated Liposome Technology, Stealth Liposome Technology, DepoFoam Liposome Technology), Application (Cancer Therapy, Fungal Diseases) – Global Outlook and Forecast 2023-2031

Endodontics Consumables Market by Product Type (Access Cavity Preparation, Shaping & Cleaning), End User (Dental Clinics, Hospitals) – Global Outlook & Forecast 2023-2031

Hypertensive Crisis Agents Market by Drug Class (Beta-blockers, Vasodilators, Calcium Channel Blockers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.